Overview

Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Collaborator:

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Treatments:

apatinib